Tidutamab

Names

[ Name ]:
Tidutamab

Biological Activity

[Description]:

Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC)[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[In Vitro]

Tidutamab (XmAb-18087; 0-100000 ng/mL)与人 SSTR2+ CHO 细胞结合，ED50 值为 2.2 μg/mL，并介导 T 细胞杀伤 SSTR2+ 靶细胞[1]。

[In Vivo]

Tidutamab (XmAb-18087; 3 mg/kg; i.p.; 单次注射) 在 NSG 小鼠中刺激人 T 细胞杀伤 SSTR2+ A549 肺癌肿瘤[1]。 Animal Model: NSG mice[1] Dosage: 3 mg/kg Administration: Intraperitoneal injection; single dose Result: lnduced anti-tumor activity in human PBMC-engrafted NSG mice.

[References]

[1]. Hyung LS, et, al. Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors. Cancer Res (2017) 77 (13_Supplement): 3633.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.